Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash.

Suppr

超能文献

作者信息

Mazhude Charles, Jones Sarah, Murad Shahed, Taylor Chris, Easterbrook Philippa

出版信息

AIDS. 2002 Jul 26;16(11):1566-8. doi: 10.1097/00002030-200207260-00020.

DOI:10.1097/00002030-200207260-00020

PMID:12131201

Abstract

摘要

相似文献

Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash.

AIDS. 2002 Jul 26;16(11):1566-8. doi: 10.1097/00002030-200207260-00020.

[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].

MMW Fortschr Med. 2001 Apr 2;143 Suppl 1:39.

Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?

AIDS. 2000 Jul 28;14(11):1672-3. doi: 10.1097/00002030-200007280-00032.

Efavirenz-associated breast hypertrophy in HIV-infection patients.

AIDS. 2001 Jan 5;15(1):126-9. doi: 10.1097/00002030-200101050-00021.

Four-drug regimens may be better.

AIDS Patient Care STDS. 2000 Dec;14(12):671. doi: 10.1089/10872910050206603.

Non-nucleoside reverse transcriptase inhibitors--an overview.

Int J STD AIDS. 2003 Feb;14(2):71-7. doi: 10.1258/095646203321156827.

Reply. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.

AIDS. 1999 Oct 1;13(14):1996. doi: 10.1097/00002030-199910010-00035.

[Efavirenz].

Rev Infirm. 2005 May(111):37-8.

Efavirenz-induced catatonia.

AIDS. 2002 Sep 6;16(13):1841-2. doi: 10.1097/00002030-200209060-00024.

Efavirenz-induced photoallergic dermatitis in HIV.

AIDS. 2001 May 25;15(8):1085-6. doi: 10.1097/00002030-200105250-00029.

引用本文的文献

Factors associated with viral load non-suppression among treatment-experienced pre-teenage children living with HIV in Kenya: a nationwide population-based cohort study, 2015-2021.

EClinicalMedicine. 2024 Feb 2;68:102454. doi: 10.1016/j.eclinm.2024.102454. eCollection 2024 Feb.

Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy.

J Acquir Immune Defic Syndr. 2020 Jun 1;84(2):203-207. doi: 10.1097/QAI.0000000000002324.

Sex-based differences in antiretroviral therapy initiation, switching and treatment interruptions: global overview from the International Epidemiologic Databases to Evaluate AIDS (IeDEA).

J Int AIDS Soc. 2018 Jun;21(6):e25149. doi: 10.1002/jia2.25149.

Barriers to a cure for HIV in women.

J Int AIDS Soc. 2016 Feb 18;19(1):20706. doi: 10.7448/IAS.19.1.20706. eCollection 2016.

How do outcomes compare between women and men living with HIV in Australia? An observational study.

Sex Health. 2016 Apr;13(2):155-61. doi: 10.1071/SH15124.

Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):85-97. doi: 10.1089/AID.2014.0205.

Caring for women living with HIV: gaps in the evidence.

J Int AIDS Soc. 2013 Oct 1;16(1):18509. doi: 10.7448/IAS.16.1.18509.

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.

J Int AIDS Soc. 2013 Sep 4;16(1):1-14. doi: 10.7448/IAS.16.1.18567.

Treating women with HIV: is it different than treating men?

Curr HIV/AIDS Rep. 2012 Jun;9(2):171-8. doi: 10.1007/s11904-012-0116-x.

Long-term safety from the raltegravir clinical development program.

Curr HIV Res. 2011 Jan;9(1):40-53. doi: 10.2174/157016211794582650.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验